36 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18873142 | COLLABORATIVE FRAMEWORKS FOR IMPROVING REGULATORY DECISION-MAKING OF MEASUREMENT SOLUTIONS | RUIZ, JOSHUA DAMIAN | 3684 | Non-Final OA | Dec 09, 2024 |
| 18799339 | Combination Therapy For Prostate Cancer | PAGANO, ALEXANDER R | 1692 | Final Rejection | Aug 09, 2024 |
| 18649184 | COMPOUNDS AND USES THEREOF | ROZOF, TIMOTHY R | 1625 | Non-Final OA | Apr 29, 2024 |
| 18528215 | RAPAMYCIN ANALOGS AND USES THEREOF | JARRELL, NOBLE E | 1699 | Non-Final OA | Dec 04, 2023 |
| 18560242 | COMBINATION THERAPIES | MCINTOSH III, TRAVISS C | 1693 | Non-Final OA | Nov 10, 2023 |
| 18558925 | DIGITAL MEASUREMENT STACKS FOR CHARACTERIZING DISEASES, MEASURING INTERVENTIONS, OR DETERMINING OUTCOMES | KANAAN, LIZA TONY | 3683 | Final Rejection | Nov 03, 2023 |
| 18557346 | MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS INHIBITORS OF MCL-1 | SHIM, DAVID M. | 1626 | Non-Final OA | Oct 26, 2023 |
| 18548747 | 4-AMINO-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 | CHICKS, ASHLI ARIANA | 1626 | Non-Final OA | Sep 01, 2023 |
| 18279556 | METHOD OF TREATING A CONDITION USING A THERAPEUTICALLY EFFECTIVE DOSE OF 1-(1-OXO-1,2-DIHYDROISOQUINOLIN-5-YL)-5-(TRIFLUOROMETHYL)-N-(2-(TRIFLUOROMETHYL)PYRIDIN-4-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | WILLIS, DOUGLAS M | 1624 | Non-Final OA | Aug 30, 2023 |
| 18546116 | MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER | PECKHAM, RICHARD GRANT | 1627 | Non-Final OA | Aug 11, 2023 |
| 18343689 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | WEIDNER, ADAM M | 1675 | Non-Final OA | Jun 28, 2023 |
| 18298580 | Methods For Ensuring Resuspension Of Paliperidone Palmitate Formulations | STIMPERT, PHILIP EARL | 3783 | Non-Final OA | Apr 11, 2023 |
| 18024104 | DRUG DELIVERY DEVICES WITH LOCK-OUT BEFORE DRUG DELIVERY | OJOFEITIMI, AYODEJI T | 3651 | Non-Final OA | Mar 01, 2023 |
| 18023632 | DRUG DELIVERY SYSTEMS AND METHODS AND DRUG PRODUCTS | GRAY, PHILLIP A | 3783 | Non-Final OA | Feb 27, 2023 |
| 18023637 | DRUG DELIVERY DEVICES WITH ON-BOARD DRUG DESTRUCTION | RUDDIE, ELLIOT S | 3785 | Non-Final OA | Feb 27, 2023 |
| 18023643 | DRUG DELIVERY DEVICES WITH A MULTI-DISPENSING HEAD | ZIEGLER, MATTHEW D | 3785 | Final Rejection | Feb 27, 2023 |
| 18022910 | DRUG SYRINGES WITH A MECHANICAL STOP FOR A SECOND DOSE | AHMED, TASNIM M | 3783 | Non-Final OA | Feb 23, 2023 |
| 18021328 | CLINICAL SUPPLY PACKS WITH ELECTRONIC LABELING | JACKSON, JORDAN L | 2857 | Final Rejection | Feb 14, 2023 |
| 18006197 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | AULAKH, CHARANJIT | 1621 | Non-Final OA | Jan 20, 2023 |
| 18004477 | LONG-ACTING FORMULATIONS | PRAGANI, RAJAN | 1614 | Non-Final OA | Jan 06, 2023 |
| 18004464 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | 1617 | Non-Final OA | Jan 06, 2023 |
| 18004336 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | 1617 | Non-Final OA | Jan 05, 2023 |
| 18002527 | SYSTEM AND METHOD FOR DETECTING OR PREDICTING RETURN IN MAJOR DEPRESSIVE DISORDER | KOLOSOWSKI-GAGER, KATHERINE | 3687 | Final Rejection | Dec 20, 2022 |
| 18084092 | BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer | HERNANDEZ, JACKSON J | 1627 | Final Rejection | Dec 19, 2022 |
| 18076567 | CRYSTAL STRUCTURE OF BTK PROTEIN AND BINDING POCKETS THEREOF | SCHULTZHAUS, JANNA NICOLE | 1685 | Non-Final OA | Dec 07, 2022 |
| 17999581 | METHODS FOR TREATING DEPRESSION | HAVLIN, ROBERT H | 1626 | Non-Final OA | Nov 22, 2022 |
| 17998198 | TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB | STOICA, ELLY GERALD | 1647 | Final Rejection | Nov 08, 2022 |
| 17998204 | PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB | RICCI, CRAIG D | 1611 | Non-Final OA | Nov 08, 2022 |
| 17998202 | TREATMENTS OF PROSTATE CANCER WITH COMBINATIONS OF ABIRATERONE ACETATE AND NIRAPARIB | IVANOVA, SVETLANA M | 1627 | Non-Final OA | Nov 08, 2022 |
| 17904139 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER | SCHMIDT, IZABELA MARIA | 1621 | Non-Final OA | Aug 12, 2022 |
| 17736305 | Formulations/Compositions Comprising a BTK Inhibitor | BORI, IBRAHIM D | 1629 | Final Rejection | May 04, 2022 |
| 17763251 | USE OF FGFR INHIBITORS IN FGFR-GENETICALLY ALTERED CANCERS TO ENHANCE PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SEQUENTIAL TREATMENT SETTINGS | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Non-Final OA | Mar 24, 2022 |
| 17528050 | Methods of Treating Prostate Cancer | CORNET, JEAN P | 1628 | Non-Final OA | Nov 16, 2021 |
| 17509889 | Methods of Reducing Tau in Human Subjects | WANG, CHANG YU | 1675 | Non-Final OA | Oct 25, 2021 |
| 17509910 | Methods of Safe Administration of Anti-Tau Antibody | FONTAINHAS, AURORA M | 1675 | Final Rejection | Oct 25, 2021 |
| 17477435 | METHODS FOR TREATING MULTIPLE MYELOMA | BENAVIDES, JENNIFER ANN | 1675 | Final Rejection | Sep 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial